Moreover, increasing evidence demonstrate that post-translational mechanisms including the release of ligands for NK cell activating receptors as soluble forms as well as ligand modification by the Ubiquitin (Ub) or Ub-like pathways are used by tumor cells to dampen activating ligand surface expression in order to evade NK cell recognition (Figure 1A). The gene discussed is NCR2; the disease is neoplasm.